MARKET

MESO

MESO

Mesoblast
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.76
-1.26
-9.68%
Closed 16:00 07/13 EDT
OPEN
12.50
PREV CLOSE
13.02
HIGH
12.54
LOW
11.70
VOLUME
639.56K
TURNOVER
--
52 WEEK HIGH
20.57
52 WEEK LOW
3.120
MARKET CAP
1.36B
P/E (TTM)
-18.5343
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MESO stock price target is 18.05 with a high estimate of 23.00 and a low estimate of 15.00.

EPS

MESO News

More
Here's Why Mesoblast Stock Rose Over 18% Today
Motley Fool · 6d ago
Why Mesoblast's Stock Is Trading Higher Today
Mesoblast (NASDAQ: MESO) shares are trading higher on Monday after company's Remestemcel-L received a compassionate use designation for children with multisystem inflammatory syndrome associated with COVID-19.
Benzinga · 07/06 18:45
FDA OKs compassionate use of Mesoblast stem cells in children with COVID-19 complications
Mesoblast (NASDAQ:MESO) initiates an expanded access protocol (EAP) in the U.S. for compassionate use of its allogeneic mesenchymal stem cell product candi
seekingalpha · 07/06 16:06
NIO, BLDP among premarket gainers
Seeking Alpha - Article · 07/06 12:17
Mesoblast to commence compassionate use of remestemcel-l in COVID-19 patients
Seeking Alpha - Article · 07/06 11:06
Expanded Access Protocol Initiated for Compassionate Use of Remestemcel-L in Children With Multisystem Inflammatory Syndrome Associated With COVID-19
GlobeNewswire · 07/06 11:00
Don't Forget Cytodyn's Other Prospects
Seeking Alpha - Article · 06/25 19:12
Here's Why Athersys Rose 26.5% in May
MotleyFool.com · 06/09 21:41

Industry

Biotechnology & Medical Research
-1.77%
Pharmaceuticals & Medical Research
-0.19%

Hot Stocks

Symbol
Price
%Change

About MESO

Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.
More

Webull offers kinds of Mesoblast limited (ADR) stock information, including NASDAQ:MESO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MESO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MESO stock methods without spending real money on the virtual paper trading platform.